The study’s small size limits interpretation, but it remains the largest real-world data available, experts said.

The drug is a fusion protein comprising the human interleukin (IL)-1 type 1 receptor (extracellular domain and accessory protein) and the Fc portion of human IgG1. Regeneron's drug is the only ...